Loading
A phase 2 trial of Oregovomab, Niraparib in ovarian cancer, run by CanariaBio Inc., active and no longer recruiting.
A Clinical Study Evaluating a Combination of Oregovomab and Niraparib in Adult Women With Platinum Sensitive Recurrent Ovarian Cancer. is a phase 2 interventional study registered as NCT05335993 by CanariaBio Inc., with 10 participants enrolled, started 2022-07-25 and due to reach its primary completion in 2026-12-30. Interventions recorded: Oregovomab, Niraparib. Conditions listed: Recurrent Ovarian Cancer, Recurrent Epithelial Cancer of Ovary, Recurrent Epithelial Ovarian Cancer, Recurrent Fallopian Tube Cancer. No results are recorded here; the registry entry is the source.
The full inclusion and exclusion criteria are on the registry record. Read 2026-10-07. Recruiting overall does not mean a particular site is open; ask the study team.
ClinicalTrials.gov data courtesy of the US National Library of Medicine.
Shares CanariaBio, Oregovomab, Ovarian cancer.
Shares CanariaBio, Oregovomab, Platinum-sensitive ovarian cancer, Ovarian cancer.
Shares CanariaBio, Oregovomab, Ovarian cancer.
Shares Niraparib, PARP inhibitors, Ovarian cancer.
Shares Niraparib, PARP inhibitors, Ovarian cancer.
Shares Platinum-sensitive ovarian cancer, PARP inhibitors, Ovarian cancer.
Shares Platinum-sensitive ovarian cancer, PARP inhibitors, Ovarian cancer.
Shares Platinum-sensitive ovarian cancer, PARP inhibitors, Ovarian cancer.
Every source this page cites, grouped by who published it. Grouping is read from the web address, not assigned by hand.
A source that has moved or gone is reported by the weekly link check. /audit/